Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$NRXP News: NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter
Study maintained 95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported.
Positive data and FDA comment would trigger the next $4 million milestone payment from partners Alvogen and Lotus and their assumption of development costs; agreement provides for up to $329 million in milestone payments and a royalty on Net Sales in the mid-teens
RADNOR, Pa., March 4, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that the 74th and last evaluable patient has completed their day 42 visit in its Phase 2b/3 study of NRX-101, the Company's patented combination of the NMDA antagonist D-cycloserine and lurasidone, in Suicidal Treatment Resistant Bipolar Depression. The database is being cleaned, finalized, and locked; statistical analysis will then be performed, with top-line data to follow shortly thereafter. As previously disclosed, positive data from this trial triggers a milestone payment from Alvogen. Alvogen will then be responsible for further development and commercialization costs for this program.
NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.
"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of 94%, well above the industry standard that is normally seen in CNS trials.
Top-line results are expected around the end of this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
https://c212.net/c/img/favicon.png?sn=CL51263&sd=2024-03-04 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html
SOURCE NRx Pharmaceuticals, Inc.
$CYIO - With the new caboncred.io launched, CYIOS leadership will continue working closely with digital marketing partner, INTENT SCIENCES with thorough GTM strategies in order to build brand awareness and to help grow the business online via SEO, social media, PR and media coverage over the next several months.
https://finance.yahoo.com/news/cyios-corp-shareholder-carboncred-carbon-150000460.html
$TWOH -- NAVIGATING THE FUTURE: THE EVOLUTION OF MICRO MERCHANT FOOD WHOLESALERS https://twohandsgroup.com/blog/micro-merchant-wholesalers-evolution
$SYNX is proud to announce that it has developed an innovative new product designed for dogs in militaries. The cutting-edge headset, having been the subject of the Company’s extensive research and engineered based on the Company’s expertise in communication technology, is designed to offer robust protection for and to enable seamless command transmission via radio directly to military dogs.https://www.nasdaq.com/press-release/silynxcom-unveils-groundbreaking-headset-for-military-dogs-offering-unparalleled
$GDHG News: Golden Heaven Group Holdings Ltd. to Expand into Indonesia Market with its Strategic Partnership
February 29, 2024
News Link:
https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-to-expand-into-indonesia-market-with-its-strategic-partnership-302074850.html
$EVKRF - Four drillholes are recommended for a Phase 1 Reverse Circulation program at the Texas Spring Property, targeting the mineralized zones identified in surface sampling.
https://finance.yahoo.com/news/grid-battery-metals-team-provides-123000945.html
$AGBA - Trusted by over 400,000 individual and corporate customers, the Group focuses on four market-leading businesses:
Platform Business, Distribution Business, Healthcare Business & FinTech Business.
https://www.agba.com/
$IVDN: Insultex House Wrap® with its unmatched R-6 rating, meets or exceeds new building codes going into effect across the US which require continuous insulation for higher thermal performance standards. Learn more at: http://insultexhousewrap.com #ContinuousInsulation #HomeBuilding
$IVDN: Insultex House Wrap® with its unmatched R-6 rating, meets or exceeds new building codes going into effect across the US which require continuous insulation for higher thermal performance standards. Learn more at: https://t.co/LWNDwJcXDh #ContinuousInsulation #HomeBuilding pic.twitter.com/jycn1smuzF
— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) February 26, 2024
1606 Corp. (OTC: $CBDW): Revolutionizing CBD Customer Service with AI Innovation https://www.redchip.com/media/2997/1606-corp-otc-cbdw-revolutionizing-cbd-customer-service-with-ai-innovation
Silynxcom Ltd $SYNX is an excellent example where fundamentals do more than support bullish sentiment; they expose opportunity. In this case, it's a compelling one. How so? Primarily because despite being better positioned to grow than any time in its history, SYNX shares are trading below its $4.00 January IPO price. From a valuation perspective, that doesn't make much sense. https://www.benzinga.com/pressreleases/24/02/ab37329501/silynxcom-stock-spikes-15-in-february-as-demand-for-its-industry-leading-in-ear-communications-eq
Stock in focus! $CBDW 1606 Corp. Launches an Era of Exceptional Growth of CBDW.ai For E-Commerce
https://cbdw.ai/1606-corp-launches-an-era-of-exceptional-growth-of-cbdw-ai-for-e-commerce/
$AVRW - Dr. Persky will be expanding his support of brand marketing, social media, and advertising campaigns for our patent-pending DNA (Deep Nano Actives) Complex an instant anti-aging skin tightening serum that due to the cutting-edge peptide technology developed exclusively for AVRW allows the ingredients to penetrate to the dermal layers of the skin.
https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html
$NICH nice loading zone here!!! https://schrts.co/anKewVnB
$TMGI - The company has successfully eliminated an additional $150,000 of its debt this year, accumulating to a total debt reduction of nearly $750,000 in under two years.
$HCTI News: Healthcare Triangle Empowers Healthcare Providers to Harness AI and LLMs for Groundbreaking Outcomes
Company’s latest initiative addresses growing demand for AI analytics to revolutionize patient care
PLEASANTON, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” HCTI” or the “Company”), a leader in transforming healthcare through technology, today unveiled an initiative aimed at enabling healthcare organizations to harness the full potential of their organic data through Artificial Intelligence (AI) and Large Language Models (LLMs).
This initiative is set against the backdrop of a rapidly expanding AI market, with Grand View Research estimating the AI in healthcare market size was $22.45 billion in 2020, and is expected to expand at a compounded annual growth rate (CAGR) of 36.4% from 2024 to 2030. Healthcare Triangle's latest offering is poised to empower healthcare providers with the tools to develop and deploy sophisticated machine learning (ML) models and LLMs, significantly enhancing patient outcomes through personalized and predictive healthcare solutions.
A Strategic Response to a Growing Demand:
The surge in the AI and analytics market highlights an escalating need for sophisticated data-driven solutions in healthcare. Healthcare Triangle's initiative strategically addresses this demand by providing a secure, scalable, and compliant digital platform. This platform facilitates the creation of AI and LLMs customized to meet the specific requirements of the healthcare industry. Through the utilization of organic data, healthcare providers gain access to valuable insights and patterns. These insights enable more precise diagnoses, efficient treatments, and ultimately, elevate the standard of patient care.
Key Features of the Initiative:
Secure and Compliant Data Utilization: Prioritizing data security and privacy, Healthcare Triangle ensures all AI and LLM development is in strict compliance with healthcare regulations, including HITRUST certification and HIPAA compliance. This commitment extends to a secure environment for data transfer, storage, and processing, alongside a comprehensive disaster recovery strategy.
Scalable Infrastructure Ready for the Future: Designed to meet the growing demands of healthcare organizations, the initiative's infrastructure is built for scalability, accommodating increasing data volumes and computational needs without compromising performance. A secure, cloud-hosted lab for LLM development highlights the initiative's readiness for the future, ensuring safety and efficiency in AI and analytics deployment.
Collaborative Ecosystem for Shared Innovation: Facilitating a culture of collaboration, the platform encourages the sharing of insights and methodologies within and between organizations, fostering a community focused on improving patient care and aligning with industry standards.
Customizable AI and LLM Development: Recognizing the diverse needs within healthcare, Healthcare Triangle offers customizable tools and solutions for developing AI and LLM models directly aligned with healthcare outcomes and objectives, ensuring flexibility and cost-effectiveness in platform service management.
A Vision for the Future of Healthcare:
"With the AI and analytics market projected to quadruple by 2024, our initiative represents a timely and necessary leap forward in empowering healthcare providers," stated Anand Kumar, Chief Revenue Officer of Healthcare Triangle. "We are not just advancing technology; we are setting a new standard for patient care, leveraging AI and LLMs to deliver personalized, predictive, and effective healthcare solutions."
As the AI and analytics market continues to grow, Healthcare Triangle's initiative marks a critical step towards realizing a future where healthcare is more personalized, outcomes are improved, and patients receive the care they need, when they need it, setting a new benchmark in healthcare innovation.
About Healthcare Triangle:
Healthcare Triangle, Inc., headquartered in Pleasanton, California, stands at the forefront of healthcare technology, specializing in AI and digital transformation. With a commitment to innovation, collaboration, and excellence, Healthcare Triangle is dedicated to reshaping healthcare delivery for the better. We collaborate with healthcare entities, including hospitals, health systems, payers, and pharma/life sciences organizations, leveraging breakthrough technology and extensive industry expertise to enhance health outcomes through optimized data utilization and cutting-edge information technologies. Holding HITRUST Certification for Cloud and Data Platform (CaDP) – featuring CloudEz™, DataEz™, and readabl.AI – our commitment to the highest standards in data protection and information security is unwavering. Healthcare Triangle serves as a beacon for the adoption of new technologies, data enlightenment, business agility, and swift response to evolving business needs and competitive challenges. Thriving in the highly regulated healthcare and life sciences sectors, we excel in digital transformation encompassing the cloud, security and compliance, identity management, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. For more information, visit www.healthcaretriangle.com
Forward-Looking Statements and Safe Harbor Notice
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K filed with the SEC on March 28, 2023, subsequent filings and future reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements.
The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release.
Contacts
Investors:
1-800-617-9550
ir@healthcaretriangle.com
https://www.globenewswire.com/newsroom/ti?nf=OTA0MjA2NSM2MDg0Mjc4IzUwMDEyMTA5OA==
https://ml.globenewswire.com/media/YjI0OWY5YWQtNmMwZC00ZGQwLTg3ODUtNzZhNjcyYjg1NzQxLTUwMDEyMTA5OA==/tiny/Healthcare-Triangle-Inc.png
Source: Healthcare Triangle, Inc
$EVKRF - Tim Fernback, Grid President & CEO comments "Clayton Valley holds the only producing lithium brine system in the United States and also holds amazing potential for lithium clay-hosted deposits.
$MMMW Mass Megawatts Announces Several New Product Lines with Lowest and Competitive Prices as a Source of Generating Revenue
https://www.globenewswire.com/news-release/2024/02/22/2833805/0/en/Mass-Megawatts-Announces-Several-New-Product-Lines-with-Lowest-and-Competitive-Prices-as-a-Source-of-Generating-Revenue.html
$EPAZ - Following a successful collaboration with the US Air Force in SBIR Award Phase 1, ZenaDrone has gained significant traction in acquiring additional contracts valued at $1.2 million
$TMGI - The Marquie Group, Inc. and its affiliate Simply Whim, via its licensor Global Holdings Network, is expected to enter into a coexistence agreement for the WHIM trademark with one of the largest beauty brands in the world.
$CRDV - Mr. Sands is a seasoned veteran in the investment community, having served in positions such as CEO, interim CFO, Director and President of both publicly traded companies and private businesses.
$GDHG News: Golden Heaven Group Holdings Ltd. Announces $6,000,000 Share Repurchase Program
NANPING, China, Feb. 22, 2024 /PRNewswire/ -- Golden Heaven Group Holdings Ltd. (the "Company" or "Golden Heaven") (Nasdaq: GDHG), an amusement park operator in China, announced today that on February 21, 2024, the Company's Board of Directors (the "Board") has authorized a share repurchase program authorizing the Company to repurchase up to US$6,000,000 of the Company's outstanding Class A ordinary shares from time to time during a 24-month period (the "Share Repurchase Program"). The Share Repurchase Program will be facilitated by Dawson James Securities, Inc.
The Board has determined that the Share Repurchase Program is in the best interest of the Company's shareholders based on its analysis and estimation that the current share price is significantly lower than the intrinsic value and that the Share Repurchase Program may improve shareholders' confidence in the Company. The Board will be periodically reviewing the Share Repurchase Program and may authorize adjustments of its terms and size.
In determining the amount of capital to allocate to share repurchases, the Company takes into account, among other things, its historical and expected business performance, cash and liquidity position, as well as global economic and market conditions and the market price of the Company's Class A ordinary shares. The timing, manner, price, and amount of any repurchases under the Share Repurchase Program are determined by the Company in its discretion. Purchases may be affected through open market transactions, privately negotiated transactions, transactions structured through investment banking institutions, or other means. The Company is not obligated to repurchase any specific number of Class A ordinary shares and the program may be modified, suspended, or discontinued at any time.
The Company intends to make all repurchases in compliance with applicable regulatory guidelines and to administer the plan in accordance with applicable laws.
About Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd. manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. With approximately 426,560 square meters of land in the aggregate, these parks are located in geographically diverse markets across the south of China and collectively offer approximately 139 rides and attractions. Due to the geographical locations of the parks and the ease of travel, the parks are easily accessible to an aggregate population of approximately 21 million people. Since September 30, 2023, Mangshi Jinsheng Amusement Park, which is one of the six parks, has been temporarily closed. The parks provide a wide range of exciting and entertaining experiences, including thrilling rides, family-friendly attractions, water attractions, gourmet festivals, circus performances, and high-tech facilities. For more information, please visit the Company's website at https://ir.jsyoule.com/.
Forward-Looking Statements
This press release contains "forward-looking statements". Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "could," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "propose," "potential," "continue" or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the U.S. Securities and Exchange Commission.
For investor and media inquiries, please contact:
Golden Heaven Group Holdings Ltd.
Email: group@jsyoule.com
Ascent Investor Relations LLC
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
View original content:https://www.prnewswire.com/news-releases/golden-heaven-group-holdings-ltd-announces-6-000-000-share-repurchase-program-302068265.html
SOURCE Golden Heaven Group Holdings Ltd.
$CBDW 1606 Corp Discover AI-driven conversational e-commerce for online retailers
$TMGI The Marquie Group Ventures into the Growing Nootropics Beverage Sector
https://finance.yahoo.com/news/marquie-group-ventures-growing-nootropics-150000857.html
$CAUD - a leading provider of digital consumer acquisition solutions.
Turtle Island Hydrogen Group and RONN Meet with Five First Nations Canada Tribal Chiefs and Energy Executives https://finance.yahoo.com/news/turtle-island-hydrogen-group-ronn-123000249.html
$EVKRF - Tim Fernback, Grid President & CEO comments "At this year's upcoming Meeting, among other corporate matters, the shareholders will be voting on the spin-out of our wholly -owned subsidiary containing our BC Nickel assets.
https://finance.yahoo.com/news/grid-battery-metals-provides-proposed-123000960.html
$CBDW Building on success of first marketing campaign
$RENB - A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-144600061.html
$DYAI Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
https://www.globenewswire.com/news-release/2024/02/21/2832746/0/en/Dyadic-Advances-Collaboration-with-Israel-Institute-for-Biological-Research-IIBR-Targeting-Bio-Threats-and-Emerging-Disease-Solutions.html
$EVKRF: Grid Battery Metals Provides Update for the Proposed Spin-out and TSX Venture listing of its subsidiary, AC/DC Battery Metals Inc.
Click here for news with images:
https://www.caledonianrecord.com/news/national/grid-battery-metals-provides-update-for-the-proposed-spin-out-and-tsx-venture-listing-of/article_c2694793-002c-5417-bf0c-25e1c88a4722.html
Building on success of first marketing campaign, $CBDW 1606 Corp launches second one with Cannasite https://finance.yahoo.com/news/building-success-first-marketing-campaign-132252227.html
$GDHG - Ms. Qiong Jin, the CEO and Chairman of the Company, commented, "This 2023 fiscal year marked a period of resilience for the Company. Our parks experienced decreases in park attendance, mainly due to facility safety maintenance from June 2023 to September 2023."
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-233000519.html
$CAUD - a leading provider of digital consumer acquisition solutions.
1606 Corp. (OTC: $CBDW): Revolutionizing CBD Customer Service with AI Innovation
$CYIO trading nearly 25% of its 10-day average volume within the first hour... UP almost 14%.
$NRXP News: NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024
HOPE shares currently owned by NRXP with planned share dividend to existing NRXP shareholders
HOPE has now completed initial manufacture of Ketamine for IV infusion and plans to file FDA New Drug Application for treatment of acute suicidality upon demonstration of 2-year shelf stability (expected Q2 2024)
HOPE plans to file patient-level data from two well-controlled clinical trials comparing ketamine to placebo in patients with acute suicidality and depression, which demonstrated a statistically significant benefit (P<.001)
HOPE plans to initiate a 506(c) pre-IPO offering of pre-IPO shares for qualified investors that is structured to potentially yield both capital appreciation and a royalty on sales of ketamine
RADNOR, Pa., Feb. 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company" , a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.
Concurrent with the presentation, NRx plans to file a proxy statement, subject to board approval, for Nasdaq:NRXP shareholders outlining the share structure and seeking a shareholder advisory vote to support the planned share dividend for HOPE Therapeutics. The Company has received consistent advice from public shareholders that the planned share dividend and royalty coupon be distributed only to shareholders and warrant-holders who execute a covenant not to participate in short sales of the Company's stock.
"Subsequent to our initial announcement of HOPE Therapeutics in December 2023, we have focused on establishing HOPE's basic corporate and board structure, securing our manufacturing partnerships and manufacturing initial productions batches of ketamine, establishing nationwide distribution, pharmacovigilance, and medical liaison partnerships, and initiating plans to pair ketamine therapy with a novel digital therapeutic that has potential to reinforce the effect of NMDA-targeted drug therapy in reducing suicidal ideation and depression," said Dr. Javitt. "We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."
Presentation Date: Monday, February 26th, 2024
Time: 2:30 PM ET
Location: The Royale Room, Marriott Marquis, New York City
Registration: https://bcic.bio.org/registration
SIMULCAST: BIZTV
Information will be available on the NRx website at https://ir.nrxpharma.com/events prior to the conference.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a wholly-owned subsidiary of NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
https://c212.net/c/img/favicon.png?sn=CL40141...2024-02-20 View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaqnrxp-to-launch-hope-therapeutics-inc-at-the-bio-ceo--investor-conference-2024-302065827.html
SOURCE NRx Pharmaceuticals
$RONN Signs Agreement with IM - 1 Development, LLC To Provide Project Development Services for Ronn's Hydrogen Pilot Programs Canada
https://finance.yahoo.com/news/ronn-signs-agreement-im-1-133000271.html
$RONN “interesting” education/information about the hydrogen market.
Just a little “interesting” education/information about the hydrogen market. $RONN pic.twitter.com/nThFTciKsq
— RONN inc (Formerly $LPHM) (@leepharma) January 24, 2024
1606 Corp. (OTC: $CBDW) Elevating CBD Customer Service Through the Power of AI
$RENB - A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
https://finance.yahoo.com/news/cutting-edge-ai-company-gedicube-144600061.html
$BNNHF Benjamin Hill Mining is a dynamic exploration company with a focus on the Alotta Exploration Project and Aion Mining Corp.’s Coal Project.
With a strong presence in the mining industry, we’re driven to uncover valuable resources in promising geological settings. Our commitment
to responsible mining practices and efficient resource utilization ensures a brighter future for all stakeholders.
$GDHG - "By drawing on the strengths of our partner, who we understand has a market base in many large cities in China, we hope to accelerate our expansion and elevate our guest experiences."
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-010000604.html
$AVRW: Leading LA Plastic Surgeon Recommends Seratopical Skin Care for Superior Anti-Aging Performance: (Stock Symbol: AVRW)
February 14, 2024
Expanding Marketing Plans in 2024 for Seratopical Skin Care: A Path to Success
Click here:
https://www.einpresswire.com/article/688477296/leading-la-plastic-surgeon-recommends-seratopical-skin-care-for-superior-anti-aging-performance-stock-symbol-avrw
$NRXP - Companies continue to work collaboratively to advance NRX-101 through registrational trials
https://finance.yahoo.com/news/nrx-pharmaceuticals-inc-nasdaq-nrxp-133000063.html
$EVKRF News: Grid Battery Metals Team Provides Nevada Exploration Update for 2024
Click here for news with images:
https://finance.yahoo.com/news/grid-battery-metals-team-provides-123000945.html
$GDHG - Looking ahead to 2024, our focus will be on utilizing the capital market and broadening our presence in the amusement park industry.
https://finance.yahoo.com/news/golden-heaven-group-holdings-ltd-130000724.html
$MDAI News: Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days
DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on the unmet need for improved medical diagnostics to allow faster and more accurate treatment decisions in wound care, today announces the appointment of Dr. J. Michael DiMaio to its Board of Directors, effective February 7, 2024. Dr. DiMaio joins the Board as a non-executive member to fill the vacancy left by the departure of Mr. Michael Murphy.
Dr. Michael DiMaio is one of the Company’s founders and previously served as the Company’s Chief Executive Officer and Chairman of the Board of Directors from 2011 to 2020. In 2020, he exited his positions with the Company and amicably resolved a dispute that had arisen at that time. He is the Chief of Staff and a practicing board-certified general, cardiac and thoracic surgeon at Baylor Scott & White-The Heart Hospitals, one of the busiest cardiovascular programs in the United States. Currently the hospitals that he oversees are rated with the highest quality scores by the Society of Thoracic Surgeons, Society of Vascular Surgery, and the American College of Cardiology. He supervises more than 650 physicians across six facilities that perform approximately 25,000 cardiovascular procedures annually.
Dr. DiMaio earned his medical degree from the University of Miami and completed his internal medicine, general surgery, and cardiothoracic surgery residencies at Duke University Medical Center and performed research under an NIH-sponsored grant. He has been elected or served as a member on many distinguished medical organizations including the American Surgical Association, Society of Thoracic Surgeons, American College of Surgeons, American Association of Thoracic Surgery, American Heart Association, American Burn Association, International Society of Heart and Lung Transplantation, American Society of Transplant Surgeons, and the Southern Thoracic Surgical Association.
He has authored nearly 500 peer-reviewed publications and abstracts, and directs a research group that has produced over 1000 publications in medical journals that include JAMA, New England Journal of Medicine, Lancet, Science, and Circulation. Dr. Michael DiMaio has served as an editorial board member or reviewer for some the most prestigious medical journals in the world and has served as a grant reviewer for the National Institutes of Health (NIH), the American Heart Association, and the U.S. Department of Defense in an addition to serving on international medical guideline committees.
In clinical trials, he has been the principal investigator for numerous medical drugs and devices that have received FDA approval and commercialization. He has been awarded over $150 million funding from the NIH, the American Heart Association, the National Science Foundation, the U.S. Department of Defense, the Department of Health and Human Services, and the Biomedical Advanced Research Development Authority (BARDA). Currently, he oversees more than 120 clinical trials at the Baylor Scott & White Research Institute and serves as Chairman of the Cardiovascular Research Review Committee for the health care system.
"I am pleased to welcome back Dr. Michael DiMaio to Spectral AI’s Board of Directors," said Richard Cotton, Chairman of the Board of Directors. "Dr. DiMaio’s deep knowledge and application of innovative medical device technologies, decades of direct patient care, and experiences within some of the United States’ preeminent medical systems and current leadership make him uniquely qualified to support the planned commercialization and ongoing development of our DeepView™ System.”
"I have spent a great deal of my career developing technologies that improve patient outcomes while delivering tangible value across the healthcare spectrum and founded this company with the intent to fill the unmet clinical need for a decision-assist device to improve wound care management,” said Dr. DiMaio. “I believe that the Company’s AI-driven wound imaging and assessment technology platform is poised to deliver on those objectives, and I am very pleased to be in a position to help advance this exciting technology towards commercialization of current and future indication developments.”
The Company also announced that Dr. DiMaio and Erich Spangenberg, who together hold approximately 45% of the Company’s outstanding shares, have each agreed to an additional six-month extension of the current lock-up of their outstanding shares pursuant to the Registration Rights/Lock-Up Agreement entered into by each of them in connection with the Company’s business combination transaction in September 2023.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Contacts
Investors
Equity Group
Devin Sullivan Conor Rodriguez
Managing Director Analyst
dsullivan@equityny.com crodriguez@equityny.com
Media
Russo Partners
David Schull
(858) 717-2310
david.schull@russopartnersllc.com
https://www.globenewswire.com/newsroom/ti?nf=OTAzNTQ5NSM2MDY1NzcyIzIyNjA4MzA=
https://ml.globenewswire.com/media/MTFkZGE0ZDMtNjVkNi00ZTNjLWJjNGItN2UxNmJjOTc4MDcyLTEyNzIzODA=/tiny/Spectral-AI-Inc-.png
Source: Spectral AI, Inc.
$GTVH News: Golden Triangle Ventures Activates Phase One of Destino Ranch Development, an Immersive Entertainment Venue, Through Its Entertainment Division
LAS VEGAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or the “Company”) has officially activated the first phase of development for the Destino Ranch Project through the execution of a land use and development agreement that provides exclusive rights to use and operate on the property. The agreement will allow for the full development of phase one of the project, which will include:
Site Event Plans and Permitting
Site Prep and Clean Out
Staff Infrastructure and Housing
Temporary Power Grid
Event Features and Infrastructure
The initial 68 acres were identified for the first phase of the project due to the approximately $3,000,000 in substantial infrastructure upgrades that have been invested into the property. These upgrades include:
Special Event Permits
Graded Roads
Fencing
Storage
Septic
Solar
Landscaping/Hardscaping
Water and Irrigation Systems
The Company is now working to secure the additional 570 acres for subsequent phases of this Flagship Project. The ultimate vision of Destino Ranch is to become a premier destination for year-round, world-class music, entertainment and art that rivals other large-scale, well-known event sites. The development is conveniently located within a short drive from large population centers such as Phoenix, Los Angeles and Las Vegas and has access to nearly 22,000 visitors traveling through the corridor per day. Beyond just music and entertainment, Destino Ranch intends to complement the beautiful, natural attributes of the Mojave Desert with a world-class art gallery, complete with rotating exhibits, large-scale permanent installations, and much more.
Steffan Dalsgaard, CEO of GTV, states: “The execution of the exclusive land use agreement is the first step for the Company in realizing the auspicious vision we have for the full development of Destino Ranch. I am confident that Destino will not only achieve the goals we have set forth for the project but will be even grander than anyone involved on the executive team had envisioned.”
To keep updated on detailed information about Destino Ranch, please visit our website and social media pages below.
Destino Ranch Website: www.DestinoRanch.com
Destino Ranch Instagram: @DestinoRanch
Destino Ranch Twitter: @DestinoRanch
About Lavish Entertainment, Inc.
Lavish Entertainment, Inc. is a wholly owned subsidiary of Golden Triangle Ventures operating under its Entertainment Division. Currently conducting its business out of Las Vegas, Nevada, the Company started doing business in 2017 and was established with a vision of becoming nationally recognized in concert production. The Company currently has more than 30,000 national followers and nearly 100 team members who have helped Lavish successfully organize some of the most exciting electronic dance music concerts in Las Vegas. Lavish Entertainment strives to produce high quality and professional events that provide an immersive experience through state-of-the-art production and sound implementation.
Lavish Entertainment recently appointed Marco Antonio Moreno as its new president and chief operations officer. Mr. Moreno is the founder, senior designer and lead project manager for ABI Create, L.L.C. (“ABI”). Formed in 2015, and based out of Phoenix, Arizona, ABI is a complete-service event management and production firm offering:
-Event Organization, Management, Production and Logistics
-Site Planning and Permitting
-Construction and Contracting
-Custom Design and Fabrication
-And More
ABI Create has successfully implemented its corporate vision of delivering high-fidelity production to large-scale installations that span major music festivals, major sporting events and notable conventions across the United States. Notable collaborative work samples include projects produced for:
-NFL Super Bowl
-San Diego & New York Comic-Con
-EDC & Camp EDC and Other Insomniac Events
-Bonnaroo Music Festival
-The Waste Management Phoenix Open and Arnold Palmer Invitational
-Burning Man
More information on Mr. Moreno along with his collaborators, partners and team can be found here https://www.abicreate.com/ or @marco.a.moreno
ABI was a crucial team member in the production of Lavish Entertainment’s Playa Playground New Year’s event (“Playa”). Held on Dec. 31, 2021, Playa was an auspicious and grand-scale Burning-Man-style music festival staged in Downtown Las Vegas that redefined the level of event that Lavish can provide. Due to the role ABI played in the execution of Playa, the CEO of Golden Triangle Ventures, Steffan Dalsgaard handpicked Mr. Moreno to lead the new vision of Lavish and contribute to the Company’s overarching business goal of becoming an industry leading, innovative and at-the-forefront music and arts entertainment production Company.
About Golden Triangle Ventures, Inc.
Golden Triangle Ventures, Inc. or “GTV” is a multifaceted consulting Company, which operates as the parent business pursuing ventures in the health, entertainment and technology sectors along with others that provide synergistic value to these three core divisions. The Company aims to purchase, acquire and/or joint venture with established entities within these areas of business. The goods and services represented are driven by innovators who have passion and commitment in these marketplaces. The Company plans to utilize relationships and create a platform for new and existing businesses to strengthen their products and/or services. The three points of the Golden Triangle exclusively represent the three sectors this Company aims to do business in. Golden Triangle Ventures is highly focused on acquiring a well-diversified portfolio of companies under one umbrella, which are all managed and owned by the Company. An amazing team of professionals support each division and continue to help the Company grow daily. Being a publicly traded Company gives the ability to provide the support needed to help each subsidiary grow into the businesses management believes they can and will become.
Golden Triangle Ventures’ business model is supported by the drive for vertical integration to cut costs and maximize margins. Management strives to acquire entities and assets that they fully understand, which maintain the prospect for long term exponential growth. The mission is to provide the necessary resources for each subsidiary to generate profit, and then allow them to leverage each other and maximize economic impact. In addition, GTV provides a professional corporate representation service to different companies in these sectors while consulting on a variety of different business development objectives.
The backbone of this business is truly a team of professional advisors looking to help companies with a multitude of corporate objectives. With an extensive rolodex of relationships, management can help with a dynamic range of project obstacles while maintaining a quality service for each client the Company represents. No matter what the needs are, the team involved can help facilitate many different transactions successfully for all parties involved. The network of relationships expands to industry experts that can assist with project management, product sourcing, industrial agriculture project implementation and so much more. Golden Triangle Ventures develops strategies and detailed plans that are custom-tailored to each corporate need and objective in all areas of business.
The GTV business model is focused on the following core group of interests:
Acquisitions / Assets / Holdings - The Company currently owns a unique portfolio of companies that are all being developed and supported by GTV, each holding a common goal of making a positive impact in the industry in which they operate.
Services - Services are deployed through Golden Triangle Ventures to assist all the unique opportunities within its operation. The Company also offers its services to select opportunities that could develop synergistic value within the relationship between both companies through the result of its efforts.
Investments - Management identifies high-value opportunities and provides capital investments in several companies and projects being developed. Each investment is complemented by a hands-on approach of helping to develop the overall direction and strategic plan for each opportunity.
http://www.GoldenTriangleInc.com
FORWARD-LOOKING INFORMATION
Certain information set forth in this press release contains "forward-looking information," including "future-oriented financial information" and "financial outlook," under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company's business, projects and joint ventures; (iv) execution of the Company's vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company's projects; (vi) completion of the Company's projects that are currently underway, in development or otherwise under consideration; (vii) renewal of the Company's current customer, supplier and other material agreements; and (viii) future liquidity, working capital and capital requirements. Forward-looking statements are provided to give potential investors the opportunity to understand management's beliefs and opinions in respect to the future so they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance, and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change, except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Securities and Exchange Commission ("SEC") has provided guidance to issuers regarding the use of social media to disclose material nonpublic information. In this regard, investors and others should note that we announce material financial information on our Company website, http://www.GoldenTriangleInc.com, in addition to SEC filings, press releases, public conference calls and webcasts. We also use social media to communicate with the public about our Company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, in light of the SEC's guidance, we encourage investors, the media and others interested in our Company to review the information we post on the following U.S. social media channels:
Twitter: http://ww.twitter.com/GTV_Inc
CONTACT INFORMATION
Golden Triangle Ventures, Inc.
3035 E Patrick Ln. #15
Las Vegas, NV 89120
info@GoldenTriangleInc.com
1-800-469-2614
Corporate Communications
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
$RWGI: Rodedawg Intl. Ind, Inc. (OTC: RWGI) Provides Shareholder Updates
Costa Mesa, CA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Rodedawg International Industries, Inc. (OTC: RWGI) proudly announces the Company, through our wholly owned subsidiary, Parabola Mgmt. LLC, has completed and submitted the application as a licensed California cannabis distributor in Coachella, California. Chris Swartz, CEO, states “We are proud to inform our shareholders that we have been making noteworthy progress toward having our licensed cannabis distribution center become an integral revenue generating operating unit of Rodedawg. As per licensing requirements, the Company paid for insurance and bonding, built fencing, installed electricity, and installed security cameras. Our recent acquisition of Parabola Mgmt., LLC coupled with this completed application has the company be on track with its first quarter 2024 milestones as per the Company roadmap. We will continue to keep shareholders apprised of the progress as this new facility will expand the revenues of the Company. We are confident that our strategically planned roadmap of expansion via acquisitions and mergers will increase 2024 revenues to meet and potentially exceed our stated goal of 7 million annually”.
Chris Swartz continues, "We couldn't have done it without this amazing team. Their hard work is making this project a success."
Mr. Swartz concludes “We will continue to provide regular updates for our shareholders as we complete our 2024 roadmap milestones during this 1st Quarter 2024. Once again, we continue to thank our loyal shareholders for their ongoing support as we create Rodedawg to becoming an industry leader in the licensed cannabis market.”
About Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries.
Please note the company Twitter address is https://twitter.com/RWGImerger for regular updates.
About Budding Horizon, LLC
Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://buddinghorizon.com/
About Brother Buds™
Brother Buds is a cannabis delivery service based in Costa Mesa, California. During the month of July 2023, the Rodedawg will operate Brother Buds under a non-storefront cannabis delivery license. The cannabis delivery service will focus on Los Angeles County, Orange County, and norther San Diego County in the demographic area of 23.86 million in 2019. The company is focused to providing management services for the licensed cannabis industry and seeks to leverage its expertise in the real estate acquisitions to acquire and develop a portfolio of assets.
The company website is https://BrotherBuds.com
Make sure to follow us at https://twitter.com/BrotherBudsOC
About Elixicure
"Elixicure is a leading provider of manufacturing and capsule encapsulation services. We offer a wide range of services to meet the diverse needs of our clients, including capsule encapsulation, formulation, manufacturing, labeling and bottle filling. Our state-of-the-art facilities and experienced team of professionals allow us to deliver high-quality products and exceptional customer service. Whether you are looking for small-scale or large-scale production, we have the expertise and capabilities to meet your needs. Contact us today to learn more about how we can support your manufacturing and encapsulation needs.
The company website is https://elixicure.com/
Make sure to follow us at https://twitter.com/Elixicure
Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements.
SOURCE: Rodedawg International Industries, Inc.
Rodedawg International Industries, Inc.
1-800-793-0355
ir@buddinghorizon.com
$CLSH - Total Revenue/Sales - $1,122,296.09 Highest Sales month on Company Record for City Trees.
https://finance.yahoo.com/news/city-trees-production-facility-achieves-130000306.html
Followers
|
525
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
45886
|
Created
|
02/21/10
|
Type
|
Free
|
Moderator MaxPowerLove$Ihub | |||
Assistants mick Ask$lapper k124Inv RoadRunner3 |
Welcome!
Sad =( Not Funny! But it's True!
Remember, The OTC Market is like Vegas! Treat trading & investing in every penny stocks like Casino gambling!
Check out some of our picks & results in the past:
Recent Plays:
Le2dynasty: Alerted for CBYI in late March @ the point when the stock was at no bid. A few weeks later the PPS reached .0004s (400% gain)
Le2dynasty: Alerted for GRPS (together with KGRI, CBYI) @ .0001s on May 17th...On May 23rd the PPS touched .0012s (1,200% gain)
Le2dynasty: Alerted for CBYI @ .0001s on May 23rd -- early morning & within a few hours, the PPS reached .0003s with mega trading volume-- (71 mil. total trading vol. with 99% buyin' vol.) (300% gain)
Le2dynasty: Alerted for CBYI @ .0002s on May 24rd -- early morning & immediately, the PPS reached .0004s with mega trading volume -- (more than 100 mil. total trading vol. CBYI was the top in top trading vol. on this day) (100% gain)
Le2dynasty: Alerted for EMLL @ .0002s on July 2nd -- early morning & the PPS reached .0004s with mega trading volume -- (more than 260 mil. total trading vol. EMLL became the top in top trading vol. & top in breakout board on this day) (50% gain)
Le2dynasty: Alerted for HIRU @ .0001s on July 3rd & on July 9, HIRU reached .0006s with mega trading volume (600% gain)
Le2dynasty: Alerted for IMDS @.0005s on July 9 @ the pt. when the total trading vol. is below 80 mil. Within 50 minutes later, the PPS reached .0009s, with more than 245 mil. total trading vol. (80% gain) in less than 1 hr. On July 10th another alert was sent out to remind traders/investors & on July 12th, the PPS reached .0026s..that is more than (500% gain) since July 9 alert.
Le2dynasty: Alerted for NVAE in early moring @ the pt. when the stock was @ no bid. PPS then reached .0003s (200% again) with a mega trading vol. (end the trading day with more than 230 mil total trading vol.). Unfortunately, the the stock dropped back to .0001 at closing.
BurntOrang3: : 400-500% gains off of DRGI after the alert
BurntOrang3: : Over 100% gains after my AUCI alert
**** Attention: Mods, Please don't edit the ibox w/o asking me first, b/c there are some kind of coding problems here ...and the IH Greeks ...Especially IH Greek (Dave) had spent a lot of time fixing this. Thank you Dave and thank all the mods here as well ****
Our Associates:
TheKingPennyStock
Daily 000X Plays
Monster Day Traders
Pinky With Potential!
BOTTOM PLAYS! CHART TECH! RESEARCH! STRATEGIES!
"A Dawgg"
Billionaire Boys Club Member Forum (BBCMF)
THE WALL STREET CLUB
$THE WAVE
THE BLUE EXCHANGE
ALERTS, CHARTS, & HOT STOCKS
Momentum Players
Momentum Runners
MOMO'S BREAKOUT BOARD
STOCKGOODIES PLAYS OF THE WEEK
Welcome To The Zoo
~~~TEFFY''S~~~HOT~~~PROFILED~~~PICKS~~~
Another Winning Trade
CASH COW
EZ Traders Forum
NO BRAINERS
StocksDiva Bio Bin
Pinto Beans and Money Making Stock Picks
PINKSHEET Breakout Board!!!
Picks For Every Play
Penny Stock Millionaire
The Van Scan
UNDERVALUED PENNY STOCKS
The Penny Stock Grow Room
Wowza board
Disclaimer: We are not investment advisors. We recommend investors to do their own due diligence. Never invest in any stock unless you can afford to lose your entire investment. Opinions expressed on this board are only opinions.
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Posts Today
|
0
|
Posts (Total)
|
45886
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |